Brincidofovir Suppliers & Bulk Manufacturers
Available Forms: Tablets / Oral suspension
Available Strengths: 100 mg, 10 mg/ml
Reference Brands: Tembexa (USA/EU)
Category:
Anti Viral
Brincidofovir is available in Tablets / Oral suspension
and strengths such as 100 mg, 10 mg/ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Brincidofovir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Brincidofovir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Brincidofovir is an oral antiviral medication and a lipid-conjugated prodrug of cidofovir designed to improve bioavailability and reduce toxicity compared to intravenous cidofovir. It is composed of cidofovir linked through its phosphonate group to a lipid, 3-hexadecyloxy-1-propanol, which facilitates efficient absorption through the intestinal wall and penetration into virus-infected cells.
Once inside target cells, brincidofovir is cleaved to release cidofovir, which is then phosphorylated by cellular enzymes to form the active metabolite, cidofovir diphosphate. This active form mimics natural nucleotides and competes with deoxycytosine-5-triphosphate (dCTP) for incorporation into viral DNA by viral DNA polymerase. Incorporation of cidofovir diphosphate into the viral DNA disrupts DNA polymerization, halts viral replication, and ultimately inhibits the proliferation of double-stranded DNA viruses.
Compared to traditional cidofovir therapy, brincidofovir offers enhanced oral bioavailability, improved cellular uptake, and reduced systemic toxicity, making it a more convenient and effective option for managing infections caused by a range of DNA viruses.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing